2021 American Transplant Congress
Characteristics, Risk Factors, and Outcomes of Neutropenia for the First Year After Liver or Kidney Transplantation in Children
*Purpose: Prior studies in adults have shown that approximately 20-38 % of subjects undergoing solid organ transplant develop neutropenia. In the current study, we characterized…2021 American Transplant Congress
Risk Factors and Outcomes of Neutropenia in Kidney Transplant Recipients
*Purpose: Neutropenia is a common side effect of valganciclovir and may pose increased risk for post-transplant infections. Medications such as mycophenolate and infections such as…2020 American Transplant Congress
Evaluation of the Safety and Efficacy of Valganciclovir to Prevent Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients Utilizing Two Dosing Regimens
Pharmacy, Ann and Robert H. Lurie Children's Hospital, Chicago, IL
*Purpose: Valganciclovir (VGCV) is FDA-approved for CMV prophylaxis in children aged one month to sixteen years old using the Pescovitz algorithm (7 x body surface…2020 American Transplant Congress
Outcomes in Liver Transplantation with Use of Granulocyte-Colony Stimulating Factor
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: Questions remain if treatment with a granulocyte-colony stimulating factor (G-CSF) impacts clinical outcomes after liver transplant. The purpose of this study was to compare…2020 American Transplant Congress
Safety and Efficacy of Prophylactic Valganciclovir Dosing after Solid Organ Transplant
Loyola University Medical Center, Maywood, IL
*Purpose: At centers where antiviral prophylaxis is used after solid organ transplant, valganciclovir is administered for the prevention of cytomegalovirus (CMV). At Loyola University Medical…2020 American Transplant Congress
Granulocyte Colony Stimulating Factor: Trigger of Rejection in Lung Transplantation?
*Purpose: Granulocyte colony stimulating factor (GCSF) is a management strategy for post-transplant neutropenia, but may increase the risk of rejection in lung transplant recipients (LTRs).…2020 American Transplant Congress
Renal Transplant Induction Therapy Safety Outcomes Comparison
*Purpose: Induction immunosuppression with alemtuzumab and rabbit anti-thymocyte globulin (r-ATG) reduces acute rejection following kidney transplantation. Efficacy is thought to be similar between the agents…2020 American Transplant Congress
Filgrastim Utilization Evaluation in Solid Organ Transplant Recipients
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: Neutropenia occurs in up to 40% of kidney and liver transplant (txp) recipients and has been associated with higher mortality rates in liver txp.…2019 American Transplant Congress
Comparison of Two Dosing Regimens of Valganciclovir for Cytomegalovirus Prophylaxis in High-Risk Liver Transplant Recipients
Michigan Medicine, Ann Arbor, MI
*Purpose: Significant controversy surrounds the optimal dose and duration of valganciclovir (VGCV) to prevent CMV in high-risk (D+/R-) liver transplant (LT) recipients. High doses cause…2019 American Transplant Congress
Efficacy of Filgrastim in Solid Organ Transplant Recipients
*Purpose: Neutropenia frequently occurs after solid organ transplantation (SOT) due to immunosuppression, antiviral prophylaxis, or viral infections. Immunosuppression reduction or antiviral prophylaxis minimization can lead…
American Transplant Congress abstracts